This month is our safety and pharmacovigilance focus, so pharmaphorum's Hannah Blake interviewed Amgen's Vice President of Global Regulatory Affairs and Safety, Alan Morrison, to find out Amgen's ...

In a brief statement, Amgen said it "does not see an association between the administration of MariTide and bone mineral density changes. The phase 1 study results do not suggest any bone safety ...

Amgen does not see an association between the administration of MariTide and bone mineral density changes," the company stated, adding, "Phase 1 study results do not suggest any bone safety ...

Amgen (NASDAQ:AMGN) shares fell in the evening hours on Tuesday after Cantor Fitzgerald argued that a potential loss of bone mineral density could be a safety risk linked to its obesity candidate ...

Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Salim Syed has given his Hold rating due to a combination of factors surrounding Amgen’s recent data on ...